explore -WSS

explore

author：leisure time 2025-09-05 11:32:58 - browse：6

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： How to use technology to prevent future drug shortages

explore

WSS

Why failed clinical trials don’t always spell doom for a new drug

IVF doctors demand details after CooperSurgical lawsuit

Streamlined flu vaccines recommended by FDA advisory panel

Why Talkspace is targeting Medicare, a tricky market

State of the Union pitch: Bigger Medicare drug price negotiations

Streamlined flu vaccines recommended by FDA advisory panel

focus

explore

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to use technology to prevent future drug shortages

New air purifier tech could be key to improving indoor air quality

Wegovy’s successful heart trial raises vital question about weight loss

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Immune cells and nerve overgrowth may explain recurring UTI pain

What does generative AI mean for health care? We asked experts

American woman, child freed after being kidnapped in Haiti last month

Guidelines to prevent youth baseball injuries need more muscle

Anavex keeps shifting the goalposts in its clinical trials

leisure time

Families look for replacement for GSK asthma drug Flovent

For AI in health care standards, federal regulators join with industry group

Emergent cuts jobs, executive role in business shake

Lack of health data on LGBTQ+ people has serious consequences

He's 19 months old and has one of the world’s rarest diseases

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

focus

explore

leisure time

hotspot